Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need
The initial indication for Aurum’s ABL-101 injectable product is in Acute Ischemic Stroke (AIS).
Globally, Stroke is a leading cause of death and disability. Only 5-10 % receive treatment and therefore, AIS is an unmet medical need.
Aurum’s patented ABL 101 platform technology represents a paradigm shift in stroke management providing both stroke therapeutic and diagnostic benefits.
Aurum is also developing this technology in other clinical indications such as inflammatory conditions, oncology, cardiovascular conditions, spinal cord injury and dementia.